Literature DB >> 28417314

Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?

Massimo Milione1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28417314     DOI： 10.1007/s12020-017-1299-0

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  14 in total

1.  ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.

Authors:  Massimo Falconi; Detlef Klaus Bartsch; Barbro Eriksson; Günter Klöppel; José M Lopes; Juan M O'Connor; Ramón Salazar; Babs G Taal; Marie Pierre Vullierme; Dermot O'Toole
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Authors:  Francesco Panzuto; Silvia Nasoni; Massimo Falconi; Vito Domenico Corleto; Gabriele Capurso; Sara Cassetta; Michela Di Fonzo; Valentina Tornatore; Massimo Milione; Stefano Angeletti; Maria Sofia Cattaruzza; Vincenzo Ziparo; Cesare Bordi; Paolo Pederzoli; Gianfranco Delle Fave
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

3.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

Review 4.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.

Authors:  E Patterson; R Webb; A Weisbrod; B Bian; M He; L Zhang; A K Holloway; R Krishna; N Nilubol; K Pacak; E Kebebew
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

6.  Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Authors:  Massimo Milione; Patrick Maisonneuve; Alessio Pellegrinelli; Sara Pusceddu; Giovanni Centonze; Francesca Dominoni; Cecilia Brambilla; Manila Rubino; Antongiulio Faggiano; Roberto Buzzoni; Laura Concas; Luca Giacomelli; Jorgelina Coppa; Vincenzo Mazzaferro; Filippo de Braud
Journal:  Endocrine       Date:  2016-11-30       Impact factor: 3.633

7.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

Authors:  S La Rosa; F Sessa; C Capella; C Riva; B E Leone; C Klersy; G Rindi; E Solcia
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

8.  The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions.

Authors:  Paolo Vercellini; Fulvia Milena Cribiù; Alessandro Del Gobbo; Maria Luisa Carcangiu; Edgardo Somigliana; Silvano Bòsari
Journal:  Fertil Steril       Date:  2013-03-07       Impact factor: 7.329

9.  The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.

Authors:  Massimo Milione; Patrick Maisonneuve; Francesca Spada; Alessio Pellegrinelli; Paola Spaggiari; Luca Albarello; Eleonora Pisa; Massimo Barberis; Alessandro Vanoli; Roberto Buzzoni; Sara Pusceddu; Laura Concas; Fausto Sessa; Enrico Solcia; Carlo Capella; Nicola Fazio; Stefano La Rosa
Journal:  Neuroendocrinology       Date:  2016-03-05       Impact factor: 4.914

10.  Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum.

Authors:  Massimo Milione; Sara Pusceddu; Patrizia Gasparini; Flavia Melotti; Patrick Maisonneuve; Vincenzo Mazzaferro; Filippo G de Braud; Giuseppe Pelosi
Journal:  Cancers (Basel)       Date:  2012-08-16       Impact factor: 6.639
View more
  3 in total

1.  KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?

Authors:  Federica Grillo; Luca Valle; Diego Ferone; Manuela Albertelli; Maria Pia Brisigotti; Giuseppe Cittadini; Alessandro Vanoli; Roberto Fiocca; Luca Mastracci
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

2.  Establishment and validation of a clinicopathological prognosis model of gastroenteropancreatic neuroendocrine carcinomas.

Authors:  Jing Chen; Yibing Liu; Ke Xu; Fei Ren; Bowen Li; Hong Sun
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

3.  Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden.

Authors:  Jayne Palmer; Oscar R Leeuwenkamp
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.